908 Devices Enhances MX908 Usability and Adds New Drug Targets

Key Terms

mass spectrometry technical

Mass spectrometry is a laboratory technique that identifies and measures chemicals by giving molecules an electrical charge and sorting them by how fast they move, like weighing and separating coins to see which kinds are present. For investors, its results are evidence used in drug development, quality control, food and environmental testing, and diagnostics, so clear mass-spec data can affect regulatory approval, product reliability, costs and market confidence.

high-pressure mass spectrometry (hpms) technical

High-pressure mass spectrometry (hpms) is a method for identifying and measuring chemicals by separating charged particles inside an instrument that operates at higher-than-normal gas pressures, which lets it analyze samples faster and with gentler handling. For investors, hpms matters because it can make laboratory testing and on-site monitoring quicker, cheaper and more portable—potentially speeding product development, improving quality control, and opening new markets for diagnostics and environmental sensing.

toxic industrial chemical technical

A toxic industrial chemical is a substance used in manufacturing, construction, or other industrial processes that can cause serious harm to people, animals, or the environment if released or mishandled. Investors should care because exposures or releases can force shutdowns, trigger regulatory fines, costly cleanups, legal claims, and damage to a company’s reputation—similar to how a gasoline spill can halt a business and create long-term bills and risks.

schedule i substance regulatory

A Schedule I substance is a drug or chemical classified by regulators as having no accepted medical use and a high potential for abuse, placing it in the most restricted legal category. Think of it as a product kept in a locked cabinet with very limited legal access; that strict status blocks routine commercial sales, makes research and development harder, and creates major legal and market risks for investors considering companies working with such compounds.

benzodiazepine medical

A benzodiazepine is a type of prescription drug that calms the brain and body to relieve anxiety, help sleep, stop seizures or relax muscles — think of it as a temporary dimmer switch for overactive nerve signals. For investors, benzodiazepines matter because their demand, safety profile, regulatory restrictions, generic competition and litigation risk can directly affect drug makers’ sales, development plans and healthcare costs.

New mission mode provides simpler and more intuitive sampling of hazardous vapors

BURLINGTON, Mass.--(BUSINESS WIRE)-- 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces new capabilities for its handheld MX908 mass spectrometry device for trace chemical identification. These enhancements include an updated mission mode for hazardous vapor sampling and the addition of five priority drug targets, providing first responders with intelligence at the point of need for an informed, confident response.

The MX908 mission modes, which include Drug Hunter, Explosives Hunter, and CW (chemical warfare) Hunter, have matured into the most powerful and complete capabilities in the device, offering broader coverage and higher confidence in results. The device’s Hazard Survey mode originally provided users with a broad, but less detailed analysis, and is now replaced with TIC (toxic industrial chemical) Hunter as a dedicated mission mode for focused hazardous vapor detection. This new mode provides first responders with a more guided and purpose-built tool that delivers clearer, faster conclusions for real-world response scenarios.

To keep pace with an evolving illicit drug landscape, five drug targets have been added to the MX908, including medetomidine, a non-opioid, veterinary sedative that is often mixed with fentanyl. Also known as ‘rhino tranq’, medetomidine is estimated to be 200 times more potent than xylazine, another veterinary sedative, making even small amounts of the drug extremely dangerous to humans. First reported in the Philadelphia drug supply in mid-2024, and spreading to other Eastern and Midwestern cities, this potent sedative causes severe withdrawal symptoms that often require intensive medical care.

Other drug targets added to MX908 include a synthetic cathinone, two synthetic cannabinoids and a benzodiazepine.

• Synthetic cathinone: N-isopropyl butylone, which has quickly emerged as the second most reported stimulant in the latter half of 2025, and is a Schedule I substance in the U.S.
• Synthetic cannabinoids: ADB-PINACA, a Schedule I substance, and MDMB-BINACA, which has been observed in the U.S., Canada, U.K., Europe, and Asia
• Benzodiazepine: Bromazolam, which is frequently found mixed with other drugs, including fentanyl

“These latest enhancements reinforce MX908’s unmatched capability for rapid trace chemical identification at the point of need,” said Trey Sieger, senior director of product management at 908 Devices. “By delivering fast, reliable results, MX908 equips law enforcement officers, military personnel, and hazmat teams with actionable intelligence they can trust to make critical decisions when every second counts.”

Customers can add these new capabilities to their MX908 device through a software update, available via the 908 Devices Customer Support Portal.

The MX908 utilizes high-pressure mass spectrometry (HPMS) for chemical identification at trace levels with exceptional sensitivity and unmatched selectively, empowering first responders to make swift, informed decisions at the point of need. The MX908 is set apart by its ability to detect trace levels of drugs, explosives and other hazardous materials in all forms—solids, liquids, vapors and aerosols. For more information about the MX908, visit https://908devices.com/products/mx908/.

About 908 Devices
908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers in vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learning. For more information, visit 908devices.com.

Forward Looking Statements for 908 Devices
This press release includes "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected uses and capabilities of the Company’s products. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under "Risk Factors" in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on March 7, 2025 and its subsequent Quarterly Reports on Form 10-Q filed with the SEC and elsewhere in the Company’s filings with the SEC which are available on the SEC's website at www.sec.gov. Additional information will be made available in the Company’s Annual Reports and Quarterly Reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260205845111/en/

Media & IR Contact

Barbara Russo

IR@908devices.com

Source: 908 Devices Inc.